Technical Analysis for IFRX - InflaRx N.V.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 1.50 | -5.06% | -0.08 |
Earnings due: Mar 20
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Stochastic Reached Oversold | Weakness | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Bullish Engulfing | Bullish | -5.06% | |
MACD Bearish Centerline Cross | Bearish | -1.32% | |
20 DMA Resistance | Bearish | -5.06% | |
NR7 | Range Contraction | -5.06% | |
Narrow Range Bar | Range Contraction | -5.06% | |
20 DMA Resistance | Bearish | -4.46% | |
50 DMA Resistance | Bearish | -4.46% |
Alert | Time |
---|---|
Possible Inside Day | about 20 hours ago |
Down 5% | about 23 hours ago |
60 Minute Opening Range Breakdown | about 23 hours ago |
Down 3% | about 23 hours ago |
Down 2 % | about 23 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 03/20/2024
InflaRx N.V. Description
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Immunology Immune System Clinical Development Autoimmune Disease Antibodies Monoclonal Antibodies Monoclonal Antibody Inflammatory Diseases Complement System Hidradenitis Suppurativa C5a
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 6.58 |
52 Week Low | 1.14 |
Average Volume | 231,343 |
200-Day Moving Average | 2.64 |
50-Day Moving Average | 1.64 |
20-Day Moving Average | 1.62 |
10-Day Moving Average | 1.62 |
Average True Range | 0.13 |
RSI (14) | 41.52 |
ADX | 12.39 |
+DI | 14.96 |
-DI | 16.50 |
Chandelier Exit (Long, 3 ATRs) | 1.54 |
Chandelier Exit (Short, 3 ATRs) | 1.78 |
Upper Bollinger Bands | 1.83 |
Lower Bollinger Band | 1.41 |
Percent B (%b) | 0.22 |
BandWidth | 26.17 |
MACD Line | -0.02 |
MACD Signal Line | 0.00 |
MACD Histogram | -0.0188 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.61 | ||||
Resistance 3 (R3) | 1.62 | 1.59 | 1.59 | ||
Resistance 2 (R2) | 1.59 | 1.57 | 1.59 | 1.58 | |
Resistance 1 (R1) | 1.55 | 1.55 | 1.54 | 1.54 | 1.58 |
Pivot Point | 1.52 | 1.52 | 1.52 | 1.52 | 1.52 |
Support 1 (S1) | 1.48 | 1.50 | 1.47 | 1.47 | 1.42 |
Support 2 (S2) | 1.45 | 1.48 | 1.45 | 1.42 | |
Support 3 (S3) | 1.41 | 1.45 | 1.41 | ||
Support 4 (S4) | 1.40 |